NQO1-Activatable Circular Antisense Oligonucleotides for Tumor-Cell-Specific Survivin Gene Silencing and Antitumor Therapy
Journal of Medicinal Chemistry · 2025
DOI: 10.1021/acs.jmedchem.4c02428 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2025. Verfasst von Xiaoran Zhao und 10 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Natural and Biomimetic Drugs, Chemical Biology Center and School of Pharmaceutical Sciences, Peking University, No. 38, Xueyu…. Hauptthemen laut MEDLINE: NAD(P)H Dehydrogenase (Quinone), Survivin, Oligonucleotides, Antisense, Gene Silencing. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 47 Literaturangaben. Gefördert von: National Key Research and Development Program of China, State Key Laboratory of Pharmaceutical Biotechnology, National Natural Science Foundation of China.
Abstract (Originalsprache)
NAD(P)H:quinone oxidoreductase-1 (NQO1), a protein highly expressed in tumor cells, serves as an excellent trigger for releasing drugs specifically within tumor cells. In this study, we designed an activatable circular antisense oligonucleotide (cASO) by incorporating a head-to-tail cyclization mediated by an NQO1-responsive trimethyl-locked quinone propionate (Q3PA), coupled with a self-immolative linker. The resulting circular structure prevented the cASO from binding to the target mRNA, thereby avoiding gene silencing. However, upon encountering NQO1, the circular form was converted to a linear form, leading to the silencing of the targeted gene. In vitro experiments demonstrated significant tumor-cell-specific activity of the cASO, while in vivo studies using an A549-Luc orthotopic lung tumor model revealed a substantial antitumor effect, primarily attributed to the suppression of survivin expression. This NQO1-activatable cASO represents a novel strategy for achieving tumor-cell-specific gene silencing and holds promise for the development of ASO prodrugs with enhanced therapeutic potentials.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Natural and Biomimetic Drugs, Chemical Biology Center and School of Pharmaceutical Sciences, Peking University, No. 38, Xueyuan Rd, Beijing 100191, China.
- Peking University Ningbo Institute of Marine Medicines, Ningbo 315832, China.
- Department of Clinical pharmacy, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China.
- Zhejiang Provincial Key Laboratory for Drug Evaluation and Clinical Research, Hangzhou 310003, China.
ORCID-Profile: Jing Wang, Zhenjun Yang, Xinjing Tang
Förderung
- National Key Research and Development Program of China
- State Key Laboratory of Pharmaceutical Biotechnology
- National Natural Science Foundation of China
Zitieren
APA
Zhao, X., Xu, J., Liang, X., Wang, Z., Zhu, Y., Guo, D., Wang, J., Amu, G., Wang, Q., Yang, Z., & Tang, X. (2025). NQO1-Activatable Circular Antisense Oligonucleotides for Tumor-Cell-Specific Survivin Gene Silencing and Antitumor Therapy. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.4c02428
Vancouver
Zhao X, Xu J, Liang X, Wang Z, Zhu Y, Guo D, et al. NQO1-Activatable Circular Antisense Oligonucleotides for Tumor-Cell-Specific Survivin Gene Silencing and Antitumor Therapy. Journal of Medicinal Chemistry. 2025. doi:10.1021/acs.jmedchem.4c02428
BibTeX
@article{Zhao2025,
author = {Zhao, Xiaoran and Xu, Jianfei and Liang, Xingxing and Wang, Zhongyu and Zhu, Yuejie and Guo, Dongyang and Wang, Jing and Amu, Gubu and Wang, Qian and Yang, Zhenjun and Tang, Xinjing},
title = {NQO1-Activatable Circular Antisense Oligonucleotides for Tumor-Cell-Specific Survivin Gene Silencing and Antitumor Therapy},
journal = {Journal of Medicinal Chemistry},
year = {2025},
doi = {10.1021/acs.jmedchem.4c02428}
}
EUVIMED